A story of survival: Saige Maxville. Saige Maxville is a warrior who was only 20 when doctors told her the brain tumor causing her seizures was cancer.
Expert: Mirvetuximab Soravtansine-Gynx Does Not Use Up the "Precious Reserves" of Patients with Ovarian Cancer pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.
CHICAGO — Mirvetuximab soravtansine-gynx extended survival of women with platinum-resistant ovarian cancer and high folate receptor-alpha expression, according to a study that compared the agent with investigator’s choice of chemotherapy.The antibody and microtubule inhibitor conjugate is the first novel therapy to show a survival benefit in a randomized phase 3 study among this
Expert suggests that mirvetuximab soravtansine-gynx, which received accelerated approval in the platinum-resistant ovarian cancer setting in 2022, is the most promising agent in more than a decade that targets folate receptor alpha.